BeOne Medicines Announces $950M IMDELLTRA Royalty Deal
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it has entered into an agreement to sell its royalty...
Tag : oncology company
BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day
BRUKINSA, sonrotoclax, and BTK CDAC data, including combinations, are designed to comprehensively address unmet needs across CLL patient populations Promising new data from pipeline assets...
BeOne Medicines Reveals Breakthrough CLL & MCL Data at EHA 2025
Clinical results from next-generation investigational therapies demonstrate potential for deep, durable responses that support the advancement of pivotal studies and future regulatory filings Phase 1...
Delcath Systems Publishes FOCUS Study Analysis on Uveal Melanoma
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of a...